Immunoglobulin News and Research

RSS

Quest Diagnostics receives FDA 510(k) clearance for Simplexa HSV 1 & 2 Direct molecular test

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that its Focus Diagnostics products business has received FDA 510(k) clearance to add the genital swab claim to its Simplexa HSV 1 & 2 Direct molecular test on the Integrated Cycler.

From Quest Diagnostics 4 Sep 2015

TMIGD1 protein could be a novel target for restoring kidney function from kidney disease

A new discovery by Boston University School of Medicine (BUSM) researchers may change how kidney disease is treated in the future.

3 Sep 2015

Research reveals why older adults who undergo general anesthesia experience postoperative delirium

Newly published research from the Department of Geriatrics and Gerontology at the Rowan University School of Osteopathic Medicine explains why up to half of older adults who undergo general anesthesia develop postoperative delirium - the sudden onset of confusion, aggression or agitated behavior that could progress to dementia. The findings indicate that older patients who are undergoing surgery may benefit from a less-potent, slower-acting anesthetic.

26 Aug 2015

AbVitro launches PairMe Grant Challenge to provide access to AbPair technology

AbVitro Inc., an immuno-oncology discovery company, today announced access to its AbPairTM technology by launching the "PairMe Grant Challenge."

20 Aug 2015

Scientists reveal how non-allergenic pollen mediators can increase allergic reactions

Scientists at Helmholtz Zentrum München and TU München discovered a new mechanism how non-allergenic pollen mediators can enhance allergic reactions. Especially the so-called B cells play a critical role in this process. The results were recently published in the Journal 'Allergy' and might lead to new approaches for therapies.

13 Aug 2015

Chronic inflammatory demyelinating polyneuropathy commonly misdiagnosed

Half of patients referred to a specialist centre with a diagnosis of chronic inflammatory demyelinating polyneuropathy do not actually have the condition, report researchers.

5 Aug 2015

Necrotising autoimmune myopathy requires early, aggressive treatment

Researchers call for the prompt recognition of necrotising autoimmune myopathy and aggressive early treatment with a combination of intravenous immune globulin, corticosteroids and a steroid-sparing agent for 3 months.

27 Jul 2015

Abingdon Health seeks distributors for newly launched Seralite - FLC diagnostic device

Following the commercial launch of Seralite - FLC Abingdon Health is looking to appoint distributors in order to enable as many people as possible affected by multiple myeloma (a cancer arising from plasma cells) to have access to, and benefit from its rapid diagnostic capabilities.

17 Jul 2015

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.

12 Jul 2015

International consensus panel reviews new diagnostic criteria for neuromyelitis optica spectrum disorder

New diagnostic criteria were introduced this week for neuromyelitis optica, now called neuromyelitis optica spectrum disorder, which is an inflammatory disease of the central nervous system that is sometimes mistaken for multiple sclerosis.

9 Jul 2015

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.

8 Jul 2015

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to its fully human monoclonal antibody Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

30 Jun 2015

UC Santa Barbara professor develops novel therapeutic strategy for PKD

For the 12 million people worldwide who suffer from polycystic kidney disease (PKD), an inherited disorder with no known cure, a new treatment option may be on the horizon.

26 Jun 2015

Autoantibodies play major role in IPF patients with acute exacerbations

Patients with acute exacerbations of idiopathic pulmonary fibrosis responded well to therapies similar to those used to treat autoimmune diseases, according to findings published today in PLOS ONE. The study suggests that autoantibodies — implicated in many autoimmune diseases such as rheumatoid arthritis or lupus — also play an important role in patients with acute exacerbations of IPF, a devastating lung disease.

18 Jun 2015

Green Cross Biotherapeutics starts construction on new biopharmaceutical facility in Montreal

This is with great pride that Green Cross Biotherapeutics Inc. kicked off construction today on its biopharmaceutical facility that will be located on the Montreal Technoparc's Saint-Laurent Campus. The CA$315 million project represents one of the largest green field investment projects in Canada in the biopharmaceutical industry, giving place to the construction of the first intravenous immunoglobulin (IVIG) and albumin manufacturing plant in Canada.

2 Jun 2015

Pre-POINT trial raises hope for Type 1 diabetes prevention

Giving oral insulin to children at genetic high risk of diabetes stimulates a regulatory immune response without inducing hypoglycaemia, show the findings of the Pre-POINT study.

1 May 2015

Civacir can effectively prevent HCV recurrence following liver transplants

New data from an ongoing Phase III trial revealed today at The International Liver Congress 2015 show that the use of hepatitis C immune globulin (HCIG, Civacir) can effectively prevent hepatitis C virus (HCV) recurrence in patients following a liver transplant (LT).

23 Apr 2015

French clinicians diagnose first case of rabies since 2003

A team of French clinicians has diagnosed the first case of rabies in that country since 2003. Only 20 cases of human rabies had been diagnosed in France between 1970 and 2003. Moreover, the patient was unaware of having been bitten.

22 Apr 2015

NIST researchers develop new 2D NMR fingerprinting method to measure monoclonal antibodies

National Institute of Standards and Technology researchers at the Institute for Bioscience and Biotechnology Research have demonstrated the most precise method yet to measure the structural configuration of monoclonal antibodies (mAbs), an important factor in determining the safety and efficacy of these biomolecules as medicines.

16 Apr 2015

Newly approved drug for rare blood cancer shows sustained benefit for 2 years

The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continued to control the rare blood cancer, with 95 percent of patients surviving for two years, report investigators from Dana-Farber Cancer Institute.

10 Apr 2015